|Other Names||Potassium voltage-gated channel subfamily KQT member 3, KQT-like 3, Potassium channel subunit alpha KvLQT3, Voltage-gated potassium channel subunit Kv73, KCNQ3|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs.|
|Cellular Location||Membrane; Multi-pass membrane protein.|
|Tissue Location||Predominantly expressed in brain.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The M channel is a slowly activating and deactivatingpotassium channel that plays a critical role in the regulation ofneuronal excitability. The M channel is formed by the associationof the protein encoded by this gene and one of two related proteinsencoded by the KCNQ2 and KCNQ5 genes, both integral membraneproteins. M channel currents are inhibited by M1 muscarinicacetylcholine receptors and activated by retigabine, a novelanti-convulsant drug. Defects in this gene are a cause of benignfamilial neonatal convulsions type 2 (BFNC2), also known asepilepsy, benign neonatal type 2 (EBN2).
Bailey, S.D., et al. Diabetes Care (2010) In press :Gomez-Posada, J.C., et al. J. Neurosci. 30(27):9316-9323(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Hahn, A., et al. Brain Dev. 31(7):515-520(2009)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.